She got captured by her own success: after she got successful, CEOs of crappy companies, like Teladoc (number 1 position in their genetics ETF) started to appro

She got captured by her own success: after she got successful, CEOs of crappy companies, like Teladoc (number 1 position in their genetics ETF) started to approach her team directly and the days of using open data for evaluating stocks was over. At this point ARK invest is looked upon as an exit strategy for startups instead of making profit. Any sane person knows that Teladoc has no experience in genetic therapeutics (unlike BEAM for example, which has a chance of fixing genetic mutations without a double stranded break...I call that disruptive innovation).